Modifiable Risk Factors for Dementia: Insights from a 15-Year Study

By Melike Belenli Gümüş

September 5, 2024

Introduction

Dementia is the second leading cause of disability-adjusted life years (DALY) in the UK, with cases expected to rise from 0.89 million in 2019 to nearly 1.6 million by 2040 due to an ageing population. Despite extensive research, no disease-modifying drugs are approved in the UK, highlighting the need to focus on modifiable risk factors (MRFs) for prevention. A 5% reduction in dementia incidence could save around £3.7 billion by 2040. Since 85% of dementia cases in the UK are in England, a recent, comprehensive 15-year study examines the evolving scenario of modifiable risk factors for dementia in England. It explores the proportion of dementia cases attributable to MRFs, identifies the primary MRFs, examines temporal trends, and assesses differences by sex and socioeconomic status (SES). The study’s insights are vital for tailoring future interventions to meet the unique needs of different groups.

Evaluating Modifiable Risk Factors

Analysing data from the English Longitudinal Study of Ageing (ELSA) between 2004 and 2009, the research reveals a slight decline in MRF population attributable fraction (PAF). However, a substantial 38% of dementia cases in 2018/2019 remain attributable to these factors. Researchers focused on identifying trends in modifiable risk factors for dementia. These factors include lifestyle choices, health conditions, and social determinants.

Lifestyle choices significantly influence dementia risk. Factors such as physical inactivity, poor diet, and smoking were identified as major contributors. Encouraging healthier lifestyles through public health campaigns can play a crucial role in dementia prevention. Promoting physical activity and balanced diets can help reduce the incidence of dementia.

Certain health conditions were found to increase dementia risk. Hypertension emerges as the primary driver, followed by obesity, social isolation, and other key factors. Managing these conditions through regular medical check-ups and appropriate treatments is essential. Early intervention can help mitigate their impact on dementia risk, improving overall health outcomes.

Addressing Sex and Socioeconomic Disparities

The study revealed notable differences in dementia risk between men and women. Women, particularly those with lower SES, are at a higher risk. These findings suggest that gender-specific strategies may be necessary to effectively mitigate dementia risk. Tailoring interventions to address these differences can enhance their effectiveness.

Figure 1. Temporal trends in population attributable fraction of 12 modifiable risk factors for dementia, 2004–2019, by sex.

SES plays a significant role in dementia risk. The study found that individuals with lower SES are more likely to develop dementia. This correlation highlights the need for targeted interventions in socioeconomically disadvantaged groups. Addressing SES-related disparities can help reduce the overall burden of dementia.

Figure 2. Temporal trends in population attributable fraction of 12 modifiable risk factors for dementia, 2004–2019, by socioeconomic status.

Implications for Policy and Practice

The findings demonstrate the persistent influence of MRFs on dementia incidence and the need for sustained efforts in preventative strategies. While successes in addressing factors like social isolation and low education are evident, challenges persist with factors such as diabetes and air pollution. The research advocates for collective-level interventions targeting risk factors across the lifespan, emphasising the importance of tailored approaches for different demographic groups.

Conclusion

By providing a nuanced understanding of dementia risk factors in England, this study offers valuable insights for shaping future preventive strategies. While advancements have been made in addressing certain risk factors, persistent challenges remain, necessitating a multifaceted approach that considers sex and socioeconomic disparities to achieve equitable healthcare outcomes and mitigate the increasing societal costs associated with dementia. Furthermore, future research should consider the impact of the COVID-19 pandemic on dementia risk. Understanding how the pandemic affects older adults and those with cognitive impairment is crucial for developing effective prevention strategies. Moving forward, targeted and sustained efforts are essential to combat the evolving scenario of dementia risk factors and reduce the burden on individuals and society.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.